Kyoung-ho Pyo

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.

Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.

Journal: Molecular cancer therapeutics

Published: June 23, 2024

Mutation-Driven Immune Microenvironments in Non-Small Cell Lung Cancer: Unrevealing Patterns through Cluster Analysis.

Mutation-Driven Immune Microenvironments in Non-Small Cell Lung Cancer: Unrevealing Patterns through Cluster Analysis.

Journal: Yonsei medical journal

Published: April 12, 2024

Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma.

Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma.

Journal: Cancer research communications

Published: April 04, 2024

Exploring the Expression and Function of T Cell Surface Markers Identified through Cellular Indexing of Transcriptomes and Epitopes by Sequencing.

Exploring the Expression and Function of T Cell Surface Markers Identified through Cellular Indexing of Transcriptomes and Epitopes by Sequencing.

Journal: Yonsei medical journal

Published: February 28, 2024

Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types.

Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types.

Journal: Frontiers in immunology

Published: November 13, 2023

CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production.

CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production.

Journal: Frontiers in immunology

Published: November 10, 2023

Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies.

Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies.

Journal: Cancers

Published: September 05, 2023

Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing.

Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing.

Journal: PloS one

Published: June 26, 2023

Editorial: Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease control.

Editorial: Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease control.

Journal: Frontiers in oncology

Published: December 11, 2022

Artificial intelligence-based non-small cell lung cancer transcriptome RNA-sequence analysis technology selection guide.

Artificial intelligence-based non-small cell lung cancer transcriptome RNA-sequence analysis technology selection guide.

Journal: Frontiers in bioengineering and biotechnology

Published: October 27, 2022

YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment.

YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment.

Journal: Frontiers in chemistry

Published: July 19, 2022

Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.

Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.

Journal: Frontiers in oncology

Published: November 24, 2021

Showing 1-12 of 45

Last Updated: 09/26/2026